Diabetes

Top Story

Starting metformin reduces risks for CV events, death in type 2 diabetes

April 20, 2017

The risks for cardiovascular events and death are decreased 6 months after metformin initiation among adults with type 2 diabetes who experience a large initial HbA1c reduction and reach HbA1c less than 6.5%, according to findings from researchers in Denmark.

Reimar Wernich Thomsen, MD, PhD, consultant and clinical associate professor in the department of clinical epidemiology at Aarhus University Hospital in Denmark, and colleagues evaluated data from patient registries in Northern Denmark on all adults (mean age, 62.5 years; 55% men) with type 2 diabetes who initiated metformin (n = 24,752) between 2000 and 2012 to determine the effect of metformin on HbA1c level and effect of HbA1c reduction on subsequent risk for CV events or death.

In the Journals Plus

Declines in CV events, mortality comparable between adults with diabetes, general population

April 17, 2017
Mortality and incidence of cardiovascular outcomes decreased in Sweden from 1998 to 2014 in adults with diabetes. Although rates of nonfatal cardiovascular events…

Cardiology Today's top stories covered at the ACC Scientific Session

April 13, 2017
The American College of Cardiology Scientific Session featured important late- break ing clinical trials and other material presented by some of the world’s…
In the Journals Plus

Statin use reduces risk for lower-limb amputation in type 2 diabetes, PAD

April 12, 2017
In adults with type 2 diabetes and peripheral artery disease, statin use was associated with a 25% lower rate of lower-extremity amputations and a 22% risk reduction in…
In the Journals Plus

NHANES: HbA1c associated with mortality risk in older adults

February 27, 2017
In older adults, an HbA1c greater than 8% was associated with increased risks for all-cause, cardiovascular and cancer-related deaths, according to…

In the Journals

Reminders tied to life, calendar events fail to increase medication adherence

February 27, 2017
Researchers tested medication reminders linked to “fresh-start” dates, defined as life and calendar events indicating the start of new…

In the Journals Plus

STAMPEDE: Sustained glycemic benefit observed 5 years after gastric bypass in type 2 diabetes, obesity

February 21, 2017
Patients with type 2 diabetes and mild to moderate obesity who underwent Roux-en-Y gastric bypass or sleeve gastrectomy saw sustained improvements in…

In the Journals

Benefits of statin therapy outweigh diabetes risk

February 20, 2017
In a commentary published in The American Journal of Medicine, experts wrote that the CV benefits of statins outweigh any diabetes-related risk they…

In the Journals

DAPT, aspirin monotherapy confer similar outcomes in patients with diabetes after CABG

February 17, 2017
New data suggest that use of dual antiplatelet therapy may not be clinically warranted in patients with diabetes post-CABG. According to data…

In the Journals

Low socioeconomic status as significant a risk factor for mortality as diabetes, high blood pressure, obesity

February 17, 2017
To reduce the risk of mortality, local and global health policies should include efforts to address low socioeconomic status as a contributor to

In the Journals Plus

Diabetes increases lifetime risk for stroke in Japanese adults

February 16, 2017
In middle-aged Japanese men and women, diabetes status is associated with residual lifetime risk for stroke, according to findings from a…

In the Journals Plus

Genetic predisposition to abdominal adiposity increases type 2 diabetes, CHD risks

February 15, 2017
The risks for type 2 diabetes and coronary heart disease were increased among adults with a genetic predisposition to higher waist-to-hip ratio…

In the Journals Plus

Dapagliflozin improves glycemic control, weight, BP in patients with type 2 diabetes, HF

February 15, 2017
Adults with concomitant type 2 diabetes and heart failure assigned dapagliflozin therapy saw reduced HbA1c, body weight and systolic blood pressure…

In the Journals

Higher SYNTAX score may predict benefit from CABG vs. medical therapy

February 6, 2017
At 5 years, elevated rates of major CV events were found in patients with diabetes and stable ischemic heart disease when baseline SYNTAX scores were…

More Headlines »
Advertisement
Advertisement